vs
Great Lakes Dredge & Dock CORP（GLDD）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Great Lakes Dredge & Dock CORP的季度营收约是Orthofix Medical Inc.的1.2倍（$256.5M vs $219.9M），Great Lakes Dredge & Dock CORP净利率更高（4.9% vs -1.0%，领先5.9%），Great Lakes Dredge & Dock CORP同比增速更快（26.5% vs 2.0%），Great Lakes Dredge & Dock CORP自由现金流更多（$50.3M vs $16.8M），过去两年Great Lakes Dredge & Dock CORP的营收复合增速更高（13.6% vs 8.0%）
大湖疏浚与码头公司是美国从事疏浚作业和填海造地工程的建筑服务商，目前是美国国内规模最大的该类服务供应商。公司业务主要集中在美国，同时有约四分之一的业务布局海外。公司原总部位于伊利诺伊州奥克布鲁克，于2020年10月迁往得克萨斯州休斯顿。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GLDD vs OFIX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $256.5M | $219.9M |
| 净利润 | $12.6M | $-2.2M |
| 毛利率 | 20.9% | 71.1% |
| 营业利润率 | 12.7% | 0.2% |
| 净利率 | 4.9% | -1.0% |
| 营收同比 | 26.5% | 2.0% |
| 净利润同比 | -35.9% | 92.4% |
| 每股收益（稀释后） | $0.19 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $256.5M | $219.9M | ||
| Q3 25 | $195.2M | $205.6M | ||
| Q2 25 | $193.8M | $203.1M | ||
| Q1 25 | $242.9M | $193.6M | ||
| Q4 24 | $202.8M | $215.7M | ||
| Q3 24 | $191.2M | $196.6M | ||
| Q2 24 | $170.1M | $198.6M | ||
| Q1 24 | $198.7M | $188.6M |
| Q4 25 | $12.6M | $-2.2M | ||
| Q3 25 | $17.7M | $-22.8M | ||
| Q2 25 | $9.7M | $-14.1M | ||
| Q1 25 | $33.4M | $-53.1M | ||
| Q4 24 | $19.7M | $-29.1M | ||
| Q3 24 | $8.9M | $-27.4M | ||
| Q2 24 | $7.7M | $-33.4M | ||
| Q1 24 | $21.0M | $-36.0M |
| Q4 25 | 20.9% | 71.1% | ||
| Q3 25 | 22.4% | 72.2% | ||
| Q2 25 | 18.9% | 68.7% | ||
| Q1 25 | 28.6% | 62.8% | ||
| Q4 24 | 24.1% | 69.0% | ||
| Q3 24 | 19.0% | 68.7% | ||
| Q2 24 | 17.5% | 67.8% | ||
| Q1 24 | 22.9% | 67.5% |
| Q4 25 | 12.7% | 0.2% | ||
| Q3 25 | 14.4% | -8.3% | ||
| Q2 25 | 8.8% | -7.9% | ||
| Q1 25 | 20.6% | -25.2% | ||
| Q4 24 | 14.8% | -5.3% | ||
| Q3 24 | 8.7% | -9.6% | ||
| Q2 24 | 8.6% | -12.5% | ||
| Q1 24 | 15.8% | -15.6% |
| Q4 25 | 4.9% | -1.0% | ||
| Q3 25 | 9.1% | -11.1% | ||
| Q2 25 | 5.0% | -6.9% | ||
| Q1 25 | 13.8% | -27.4% | ||
| Q4 24 | 9.7% | -13.5% | ||
| Q3 24 | 4.6% | -13.9% | ||
| Q2 24 | 4.5% | -16.8% | ||
| Q1 24 | 10.6% | -19.1% |
| Q4 25 | $0.19 | $-0.05 | ||
| Q3 25 | $0.26 | $-0.57 | ||
| Q2 25 | $0.14 | $-0.36 | ||
| Q1 25 | $0.49 | $-1.35 | ||
| Q4 24 | $0.29 | $-0.76 | ||
| Q3 24 | $0.13 | $-0.71 | ||
| Q2 24 | $0.11 | $-0.88 | ||
| Q1 24 | $0.31 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.4M | $82.0M |
| 总债务越低越好 | $378.2M | — |
| 股东权益账面价值 | $517.1M | $450.0M |
| 总资产 | $1.3B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
| Q4 25 | $13.4M | $82.0M | ||
| Q3 25 | $12.7M | $62.9M | ||
| Q2 25 | $2.9M | $65.6M | ||
| Q1 25 | $11.3M | $58.0M | ||
| Q4 24 | $10.2M | $83.2M | ||
| Q3 24 | $12.0M | $30.1M | ||
| Q2 24 | $23.1M | $26.4M | ||
| Q1 24 | $22.8M | $27.0M |
| Q4 25 | $378.2M | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $448.2M | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
| Q4 25 | $517.1M | $450.0M | ||
| Q3 25 | $502.1M | $442.5M | ||
| Q2 25 | $481.9M | $458.3M | ||
| Q1 25 | $479.9M | $458.3M | ||
| Q4 24 | $448.9M | $503.1M | ||
| Q3 24 | $425.4M | $525.9M | ||
| Q2 24 | $418.0M | $546.0M | ||
| Q1 24 | $409.0M | $570.3M |
| Q4 25 | $1.3B | $850.6M | ||
| Q3 25 | $1.3B | $832.6M | ||
| Q2 25 | $1.2B | $837.2M | ||
| Q1 25 | $1.2B | $823.1M | ||
| Q4 24 | $1.3B | $893.3M | ||
| Q3 24 | $1.1B | $867.9M | ||
| Q2 24 | $1.1B | $882.0M | ||
| Q1 24 | $1.1B | $906.0M |
| Q4 25 | 0.73× | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 1.00× | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $79.7M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $50.3M | $16.8M |
| 自由现金流率自由现金流/营收 | 19.6% | 7.6% |
| 资本支出强度资本支出/营收 | 11.5% | 4.9% |
| 现金转化率经营现金流/净利润 | 6.31× | — |
| 过去12个月自由现金流最近4个季度 | $99.5M | $-1.3M |
8季度趋势，按日历期对齐
| Q4 25 | $79.7M | $27.7M | ||
| Q3 25 | $49.2M | $12.4M | ||
| Q2 25 | $56.9M | $11.6M | ||
| Q1 25 | $60.9M | $-18.4M | ||
| Q4 24 | $-13.5M | $23.7M | ||
| Q3 24 | $26.8M | $11.7M | ||
| Q2 24 | $18.4M | $9.0M | ||
| Q1 24 | $38.4M | $-18.6M |
| Q4 25 | $50.3M | $16.8M | ||
| Q3 25 | $13.2M | $2.5M | ||
| Q2 25 | $-3.7M | $4.5M | ||
| Q1 25 | $39.6M | $-25.1M | ||
| Q4 24 | $-36.1M | $15.2M | ||
| Q3 24 | $-11.5M | $6.3M | ||
| Q2 24 | $-34.0M | $-360.0K | ||
| Q1 24 | $26.5M | $-29.1M |
| Q4 25 | 19.6% | 7.6% | ||
| Q3 25 | 6.8% | 1.2% | ||
| Q2 25 | -1.9% | 2.2% | ||
| Q1 25 | 16.3% | -13.0% | ||
| Q4 24 | -17.8% | 7.0% | ||
| Q3 24 | -6.0% | 3.2% | ||
| Q2 24 | -20.0% | -0.2% | ||
| Q1 24 | 13.4% | -15.4% |
| Q4 25 | 11.5% | 4.9% | ||
| Q3 25 | 18.4% | 4.8% | ||
| Q2 25 | 31.3% | 3.5% | ||
| Q1 25 | 8.7% | 3.5% | ||
| Q4 24 | 11.2% | 4.0% | ||
| Q3 24 | 20.0% | 2.7% | ||
| Q2 24 | 30.8% | 4.7% | ||
| Q1 24 | 6.0% | 5.6% |
| Q4 25 | 6.31× | — | ||
| Q3 25 | 2.77× | — | ||
| Q2 25 | 5.87× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | -0.69× | — | ||
| Q3 24 | 3.02× | — | ||
| Q2 24 | 2.39× | — | ||
| Q1 24 | 1.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GLDD
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
